Biotech Investors Reach $32.5M Deal Over Failed COVID Test

By Gina Kim · October 1, 2024, 6:03 PM EDT

A class of Talis Biomedical Corp. investors accusing the company of inflating their stock price in the run-up to its IPO and then failing to launch a COVID-19 diagnostic test asked...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Settlement

Case Information

Case Title

IN RE Talis Biomedical Securities Litigation

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2022

Recent Articles By Gina

October 02, 2024
Pfizer Didn't Warn Of Tumor Risks In Depo-Provera, Suit Says
October 01, 2024
Premier Health Sued For Age Bias By Ex-Regional Director
September 27, 2024
Acadia To Pay $19.9M For Alleged Inpatient Billing Scheme
September 26, 2024
Senate Bill Calls For Stronger Healthcare Cyber Standards
September 26, 2024
NY Lawmakers Beat ADA Suit Over Contentious Mask Ban
August 28, 2024
Mont. Hospital Pays $11M In FCA Case For Doc's Fake Billing
August 02, 2024
Fla.'s Trans Healthcare Ban Violates Title VII, Judge Says
August 01, 2024
Male Sex Drug Labeled As 'Natural' Contains Viagra, Suit Says
July 30, 2024
Rite Aid Sued Over Data Breach That Affected 2.2M Customers
July 23, 2024
Optum Can Arbitrate Calif. Healthcare Provider's Antitrust Suit